Monday, October 19, 2026
BTC $82,383 ▲ 0.46%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.219down−1.08%ETH$2,425up+0.74%LINK$12.11up+0.68%SOL$105.04up+1.02%BTC$82,383up+0.46%XRP$1.31up+0.06%S&P 5007,659down−1.09%Nasdaq26,140down−2.14%Dow52,002down−0.34%RUT2,721down−1.66%TNX5.10%up+0.18%TYX5.44%up+0.13%FVX4.90%up+0.00%IRX4.07%down−0.44%VIX18.62down−6.85%GOLD$4,188.70up+0.18%SILVER$57.73up+0.73%OIL$98.40down−0.63%DXY101.95up+0.11%NVDA$214.13down−1.43%AAPL$343.46up+0.43%TSLA$354.72down−2.13%META$709.33down−3.72%MSFT$529.05down−1.93%AMZN$250.00down−1.87%GOOGL$340.59down−2.47%Fear & Greed59 — GreedADA$0.219down−1.08%ETH$2,425up+0.74%LINK$12.11up+0.68%SOL$105.04up+1.02%BTC$82,383up+0.46%XRP$1.31up+0.06%S&P 5007,659down−1.09%Nasdaq26,140down−2.14%Dow52,002down−0.34%RUT2,721down−1.66%TNX5.10%up+0.18%TYX5.44%up+0.13%FVX4.90%up+0.00%IRX4.07%down−0.44%VIX18.62down−6.85%GOLD$4,188.70up+0.18%SILVER$57.73up+0.73%OIL$98.40down−0.63%DXY101.95up+0.11%NVDA$214.13down−1.43%AAPL$343.46up+0.43%TSLA$354.72down−2.13%META$709.33down−3.72%MSFT$529.05down−1.93%AMZN$250.00down−1.87%GOOGL$340.59down−2.47%Fear & Greed59 — Greed
Tag

intismeran

1 article

Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Research & Analysis60d ago
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.